The Council of Scientific and Industrial Research on Thursday announced that Mumbai-based pharmaceutical firm Cipla is all set to launch drug Favipiravir for the treatment of COVID-19 patients. "Cipla has scaled up the process in their manufacturing facility and approached DCGI (Drug Controller General of India) for permission to launch the product in India. Given that DCGI has given restricted emergency use for Favipiravir in the country, Cipla is now all set to launch the product to help patients suffering from COVID-19," a statement provided by CSIR read. India has yet again witnessed its highest single-day spike of COVID-19 cases with 49,310 cases reported in the last 24 hours, according to data from the Union Ministry of Health and Family Welfare. Maharashtra remains the worst affected state with 3,47,502 cases reported until Thursday.

Source: dna July 24, 2020 07:52 UTC